Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Lenalidomide/Rituximab Combo Nears EU Approval for Follicular Lymphoma

November 15th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the combination of lenalidomide and rituximab for the treatment of adult patients with grade 1 to 3a previously treated follicular lymphoma.

Rapid Growth of Targeted Therapies in AML Spurs Need for More Learning

November 14th 2019

During a recent OncLive Peer Exchange® program, a panel of leukemia experts provided an overview of these agents and shared their perspectives on how clinicians can incorporate them into their clinical practice.

KD025 Hits High Response Rate in Chronic GVHD

November 12th 2019

Treatment with the selective ROCK2 inhibitor KD025 led to statistically significant overall response rates in patients with chronic graft-versus-host disease who have received ≥2 prior lines of systemic therapy.

Investigators Link Novel Biomarker to Therapy in DLBCL Trial

November 12th 2019

Investigators are exploring the novel genetic biomarker DGM1 as a potential predictor of benefit from the experimental agent enzastaurin in treatment-naïve patients with high-risk diffuse large B-cell lymphoma.

FDA Approves Luspatercept for Beta Thalassemia–Associated Anemia

November 8th 2019

The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

Ixazomib Improves PFS as Frontline Maintenance in Multiple Myeloma

November 7th 2019

Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.

Novel Combinations Could Improve Cure Rates for Adult ALL

November 7th 2019

Novel combinations of biologic therapies, third-generation TKIs, and chemotherapy could lead to significantly higher cure rates for adult patients with acute lymphoblastic leukemia, with a number of early stage studies already showing promising results, according to Hagop M. Kantarjian, MD, at the 37th Annual CFS®.

Expert Explains Treatment Considerations in Newly Diagnosed Follicular Lymphoma

November 7th 2019

Given that a watch-and-wait approach is a viable option, clinicians must carefully consider disease characteristics when selecting a treatment strategy in newly diagnosed follicular lymphoma.

New Sequencing Approaches Shape Follicular Lymphoma Landscape

November 6th 2019

With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging.

Dr. Zain on Targets Under Investigation in T-Cell Lymphomas

November 6th 2019

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.

NEJM Data Highlight Gilteritinib Survival Benefit in FLT3+ AML

November 1st 2019

Gilteritinib demonstrated a higher remission rate and a statistically significant improvement in overall survival compared with salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia who harbor a FLT3 mutation.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Umbralisib Hits Primary Endpoint in Follicular Lymphoma Subgroup of Pivotal Study

October 29th 2019

Umbralisib (TGR-1202) met the primary endpoint of overall response rate in the follicular lymphoma cohort of the pivotal phase IIb UNITY-NHL trial, according to TG Therapeutics, Inc., the developer of the PI3K-delta inhibitor.

Iomab-B Leads to High Bone Marrow Transplant Rate in Relapsed/Refractory AML

October 29th 2019

Treatment with iodine-131 apamistamab led to a high bone marrow transplant rate compared with salvage chemotherapy in elderly patients with relapsed/refractory acute myeloid leukemia.

Gilteritinib Approved in Europe for Relapsed/Refractory FLT3+ AML

October 25th 2019

The European Commission has approved gilteritinib as a single agent for the treatment of relapsed/refractory patients with FLT3-mutant acute myeloid leukemia.

Dr. Babushok on Treatment Advances in Paroxysmal Nocturnal Hemoglobinuria

October 24th 2019

Daria V. Babushok, MD, PhD, discusses treatment advances in paroxysmal nocturnal hemoglobinuria.

Dr. Perl on Challenges of Implementing Immunotherapy in AML

October 23rd 2019

Alexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.

Dr. Schiller on the Heterogeneity of AML

October 19th 2019

Gary J. Schiller, MD, discusses the heterogeneity of acute myeloid leukemia.

Rituximab Sets the Pace in Changing Lymphoma Landscape

October 18th 2019

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

FDA Label Update Supports Earlier Use of Romiplostim for ITP

October 18th 2019

The FDA has approved a supplemental Biologics License Application for romiplostim, updating its label to include data demonstrating sustained platelet responses in adults with immune thrombocytopenia. Romiplostim is approved for the treatment of adult patients with newly diagnosed or persistent who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.